ZYME - Zymeworks Inc.
37.15 0.00 (0.00%)
After hours: 5:07PM EDT
Chart Events
Commodity Channel Index
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 38.12 |
| Open | 38.21 |
| Bid | 37.08 x 1100 |
| Ask | 38.80 x 800 |
| Day's Range | 37.01 - 38.96 |
| 52 Week Range | 17.60 - 52.75 |
| Volume | 496,548 |
| Avg. Volume | 460,022 |
| Market Cap | 1.692B |
| Beta (5Y Monthly) | 1.18 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.87 |
| Earnings Date | Aug 03, 2020 - Aug 10, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 24.88 |
Fair Value
Related Research
- Business Wire
Zymeworks to Present at the Jefferies 2020 Virtual Healthcare Conference
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that the Company will present at the upcoming Jefferies 2020 Virtual Healthcare Conference taking place June 2-4, 2020.
- Business Wire
Zymeworks Announces Election of Directors and Voting Results from Shareholder Meeting
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, is pleased to announce the detailed voting results on the items of business considered at its Annual General Meeting of Shareholders held on May 7, 2020 (the "Meeting").
- Zacks
Zymeworks Inc (ZYME) Reports Q1 Loss, Tops Revenue Estimates
Zymeworks Inc (ZYME) delivered earnings and revenue surprises of 28.89% and 6.24%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
Zymeworks Reports 2020 First Quarter Financial Results
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the first quarter ended March 31, 2020.
- Zacks
Earnings Preview: Zymeworks Inc. (ZYME) Q1 Earnings Expected to Decline
Zymeworks Inc. (ZYME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Insider Monkey
Hedge Funds Have Never Been This Bullish On Zymeworks Inc. (ZYME)
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
- Business Wire
Zymeworks Announces First Patient Dosed in Phase 1b/2 Trial of ZW25 in First-Line HER2-Positive Breast Cancer and Gastroesophageal Adenocarcinoma Conducted by BeiGene
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that its partner, BeiGene, Ltd., has dosed the first patient in a two-arm Phase 1b/2 trial evaluating Zymeworks’ HER2-targeted bispecific antibody ZW25 in combination with chemotherapy as a first-line treatment for patients with metastatic HER2-positive breast cancer and in combination with chemotherapy and BeiGene’s PD-1-targeted antibody tislelizumab as a first-line treatment for patients with metastatic HER2-positive gastroesophageal adenocarcinoma (GEA). Zymeworks will receive a payment under its collaboration with BeiGene as a result of the achievement of this development milestone.
- Business Wire
Zymeworks Appoints Dr. Kelvin Neu to the Board of Directors
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the appointment of Kelvin Neu, M.D., to its Board of Directors.
- Zacks
Zymeworks Inc. (ZYME) Reports Q4 Loss, Lags Revenue Estimates
Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of -97.62% and -79.64%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
Zymeworks Reports 2019 Year-End Financial Results
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the year ended December 31, 2019.
- Zacks
Analysts Estimate Zymeworks Inc. (ZYME) to Report a Decline in Earnings: What to Look Out for
Zymeworks Inc. (ZYME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- TipRanks
Deutsche Bank: 3 “Strong Buy” Stocks to Snap Up Now
Looking for fresh investing ideas as we wrap up 2019? You’re not alone. Investors are hitting the Street, searching high and low for the most compelling opportunities to snap up this holiday season. Stocks worthy of a place in investors’ stockings are the names not only poised to outperform but also backed by the Street’s analysts.As investors hunt for stock market deals, they are also looking to the pros for some guidance as to what the economic landscape looks like going into 2020. Deutsche Bank Group Chief Economist, David Folkerts-Landau, tells clients that he expects the S&P 500 to climb higher through the first quarter of 2020.“We believe that after a globally synchronized slow down over the past 18 months global growth is now bottoming out well short of recession territory and will get back on track early next year. While activity may slow a bit further from its current levels in the near term, we are optimistic when looking forward several quarters. Uncertainty about trade policy and national politics are getting resolved, there is limited inventory overhang, and the still unprecedented monetary easing is feeding through into the global economy,” he stated.Deutsche Bank’s analysts are some of the best-performing on Wall Street, with their selections offering plenty of investing inspiration. Not to mention the firm ranks within the top 10 of TipRanks’ Top Performing Research Firms. With this in mind, we wanted to check out 3 of Deutsche Bank’s stock picks. Upon closer inspection with the use of TipRanks' Stock Screener tool, we found out that the rest of the Street is also in favor of these names, as each has earned a “Strong Buy” consensus rating.Uber Technologies (UBER)The popular ride sharing platform has found itself in hot water recently over its operations in London. That being said, Deutsche Bank analyst Lloyd Walmsley actually sees the stock “clawing” its way back after bad news as a positive.The trouble for Uber started when it lost its license to operate in London thanks to a few key issues brought up by the Transport for London (TfL). The company had been letting unauthorized drivers upload pictures to other Uber accounts as well as allowed suspended or dismissed drivers to create accounts. Adding fuel to the fire, the TfL found “several insurance-related issues” including drivers working without proper insurance. Uber can appeal the decision, with the Wall Street Journal stating that the appeal process could take eight months, during which time the company would still be allowed to operate.As Walmsley estimates that London accounts for 5% of Uber’s bookings, or about $2.5 billion in 2019, it’s no wonder some investors are worried. Nonetheless, the five-star analyst tells clients that based on conversations with industry sources, he thinks Uber will most likely continue to operate.“We think Uber will get a license given (1) the new leadership at the company under Dara Khosrowshahi has been making bona fide efforts to improve the safety of the app, work with regulators, and generally improve the culture (e.g. "Do the right thing, period") (2) it is working transparently with regulators, including in London, and the Transport for London (TfL) itself acknowledged such in its press release, and (3) while channel feedback was (not surprisingly) mixed here, one competitor noted Uber's safety processes are as good, if not better than, the other players in the market,” the analyst explained.With Walmsley adding that the CEO’s recent insider buying, the passing of the lockup expiration, improving competitive and profitability trends in the U.S. and Latin America, tighter private capital markets and improving disclosure point to shares gaining in the long-run, he kept the Buy recommendation. At the $50 price target, the upside potential is 69%. (To watch Walmsley’s track record, click here)All in all, other analysts agree that Uber still looks like a long-term winner. With 21 Buy ratings vs 5 Holds, the stock is a Strong Buy. While slightly below Walmsley’s forecast, the $45.52 average price target suggests solid upside potential of 60%. (See Uber stock analysis on TipRanks)Zymeworks (ZYME)Zymeworks wants to help bring patients home disease free, developing treatments for various forms of cancer as well as tumors. After gaining 187% year-to-date, the biotech company is definitely on the Street’s radar.During the ESMO Asia 2019, the company provided an update on the first part of the Phase 1 trial evaluating single-agent ZW25 in HER2+ cancers, not including breast cancer. The data demonstrated that response rates improved for colorectal cancer and gastroesophageal adenocarcinoma, with ZW25's safety profile still looking promising. Most noteworthy, however, was that one pancreatic cancer patient experienced a 100% decrease in target lesions.“Overall, we view the ESMO Asia update as continuing to support the broad activity of ZW25 monotherapy in HER2+ cancers, especially in HER2-high cancers, with a safety profile that appears highly amenable to combination approaches. Further, first responses in duodenal and pancreatic tumors expand the breadth of that clinical activity and provide more reasons for us to be enthusiastic with regard to the company,” Deutsche Bank’s Konstantinos Aprilakis commented.As the analyst also highlights the “potential opportunity for accelerated approval given the lack of any targeted HER2 therapies approved in this setting,” he keep his Buy recommendation. Adding to the good news, Aprilakis bumped up the price target by $10 to $49, implying shares could surge 16% in the next twelve months. (To watch Aprilakis’ track record, click here)When it comes to the rest of the Street, let’s just say they’ve been pretty impressed with ZYME. Out of 6 analysts that have issued ratings in the last three months, 5 Buys were given compared to 1 Hold. Additionally, the $51 average price target brings the upside potential to 21%. (See Zymeworks stock analysis on TipRanks)PTC Inc. (PTC)In terms of digital transformation, PTC is leading the way. With its innovative software solutions, the company provides customers with the capabilities they need to succeed. While PTC has struggled year-to-date, Deutsche Bank’s Alex Tout believes the current share price represents an attractive entry point.At its investor event in Boston, Massachusetts, the company restated its goal of $850 million free cash flow by full year 2024, or 31% full year 2019 through 2024 CAGR.Tout argues that this target appears attainable as the prediction is in line with its blended end markets, noting, “While we think investors may still need some convincing that PTC’s ARR growth outlook to FY24 is realistic given the performance in FY19, fundamentally we believe that some acceleration from FY19's level of ARR growth is likely, not least as PTC’s high-growth IoT/AR business (as well as, now, Onshape) becomes an ever larger part of the mix and the headwind from the ‘Productivity Zone’/FSG reduces.”According to the analyst, PTC’s acquisition of Onshape could lift its historical growth rate as the addition helps PTC cater to SMB companies that were previously out of its reach. On top of this, the company has partnerships with Microsoft, Ansys and Rockwell Automation that are still being developed.Taking all this into consideration, Tout maintained the bullish call. While he did lower the price target from $105 to $95, he still sees 24% upside potential in store. (To watch Tout’s track record, click here)Similarly, the rest of the Street is getting onboard. 5 Buys and 1 Hold assigned in the last three months add up to a Strong Buy analyst consensus. In addition, the $87 average price target puts the potential twelve-month gain at 15%. (See PTC stock analysis on TipRanks)
- Benzinga
The Daily Biotech Pulse: Roche-Spark Deal Extended Again, Zymeworks' Positive Readout, Enanta Misses Earnings Estimate
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Nov. 21.) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Alnylam ...
- Zacks
Zymeworks Inc. (ZYME) Reports Q3 Loss, Tops Revenue Estimates
Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of -1.45% and 1.22%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Earnings Preview: Zymeworks Inc. (ZYME) Q3 Earnings Expected to Decline
Zymeworks Inc. (ZYME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Insider Monkey
Hedge Funds Have Never Been More Bullish On Zymeworks Inc. (ZYME)
We are still in an overall bull market and many stocks that smart money investors were piling into surged through October 17th. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 45% and 39% respectively. Hedge funds' top 3 stock picks returned 34.4% this year and beat the S&P […]
- Benzinga
Raymond James Upgrades Zymeworks, Says Encouraging Cancer Drug Is 'Born to Run'
Canadian biotech Zymeworks Inc . (NYSE: ZYME ) over the weekend announced more data from an ongoing clinical trial of a drug to treat HER2-type cancers and announced a Phase 2 trial in another cancer drug, ...
- TipRanks
4 Defensible Healthcare Stocks Gaining While the Market Falls
With the latest escalation of the U.S.-China trade war on August 23, investors are looking for defensible stocks that still represent compelling investments in a volatile market. According to research from Goldman Sachs, these investments can be found within the healthcare sector. “Funds have steadily reduced the share of market cap owned among the stocks most exposed to US-China trade conflict, such as semiconductors,” Goldman strategist Ben Snider wrote in a note to clients. He added that even with the risk of health care regulation that attracted attention from investors earlier in the year, healthcare stocks still present a strong opportunity given the economic landscape. We looked at 4 of the top August 23 gainers in this sector to find the most compelling investments. Let’s dive in. Endologix, Inc. (ELGX)Endologix develops innovative and minimally invasive technologies for aortic disorders including abdominal aortic aneurysms (AAA). With shares gaining 4% on August 23, some analysts argue this healthcare stock is just getting started. The jump comes one day after ELGX canceled its agreement with Piper Jaffray for the at-the-market sale of up to $25 million of its common stock. While this would have given the company additional capital, several recent positive developments suggest ELGX is still on track for long-term growth.On August 8, the company announced its agreement to give Boston Scientific (BSX) exclusive rights to distribute its Endologix products in China. Not to mention that same day it received Investigational Device Exemption (IDE) approval from the FDA to begin a new pivotal study evaluating the safety and effectiveness of the Nellix Chimney EndoVascular Aneurysm Sealing System (ChEVAS) for endovascular treatment of complex AAA.Based on all of the above factors, BTIG analyst Sean Lavin reiterated his Buy rating and $12 price target on August 12. The 3.5-star analyst believes share prices could soar 118% over the next twelve months.All in all, the Street is cautiously optimistic on this healthcare stock. ELGX has a ‘Moderate Buy’ analyst consensus and an $8 average price target, suggesting 51% upside. T2 Biosystems Inc. (TTOO) This healthcare stock develops and commercializes medical diagnostic products for the detection of additional species and antibiotic resistance markers of sepsis pathogens as well as tests for Lyme disease. In the last five days, shares are up 49% with shares gaining over 3% on August 23 alone.Shares got a boost shortly after T2 announced that it had entered into an exclusive agreement that will allow the company to introduce its rapid diagnostic technologies, including the T2Bacteria and T2Candida Panels, and enter into new markets in Australia, Fiji and New Zealand. These countries have approximately 1,150 hospitals that could benefit from T2’s products. It doesn’t hurt that its T2Bacteria Panel received approval for a New Technology Add-on Payment (NTAP) from the Centers for Medicare & Medicaid Services (CMS) on August 6, making it the first and only in-vitro diagnostic test to ever receive approval for NTAP.“We view this development as an unexpected victory that sort of came out of left field (as management had not indicated plans to pursue this add- on payment). While management has indicated that pricing (cost) of their panels has historically not been a meaningful barrier to driving adoption, we think that anything sold into a hospital is scrutinized from a cost and ROI perspective, even if it is clear that the technology has clinical utility for the patient,” noted Canaccord Genuity analyst Mark Massaro. As a result, the five-star analyst reiterated his Buy rating and $2.50 price target on August 6. He believes shares could soar 110% over the next twelve months. Wall Street takes a less bullish stance on TTOO. It has a ‘Hold’ analyst consensus and a $1 average price target, indicating 22% upside potential. InspireMD Inc. (NSPR)The vascular procedure technology company saw shares jump almost 2% on August 23 as well as a 32% gain in the last five days, with some analysts saying there’s no sign of a slowdown on the horizon.The upward move follows the announcement of its planned public offering of units, each consisting of one common share and one Series E warrant. Investors have expressed concern regarding a letter from the NYSE American it received on August 7, 2019. It indicated that InspireMD does not meet a certain listing standards due to the fact that the company had reported stockholders’ equity of less than $6 million as of June 30, 2019 and had net losses in its five most recent fiscal years. That being said, analyst Vernon Bernardino argues that the public offering is a move in the right direction. As a result, he reiterated his Buy rating and $5 price target. The H.C. Wainwright analyst believes shares could surge 71% in the next twelve months. NSPR boasts a ‘Moderate Buy’ analyst consensus and a $5 average price target, implying 71% upside potential. Zymeworks Inc. (ZYME)This biotech company develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. With shares up over 1% on August 23, some analysts believe now is the time to buy.Investors were impressed when ZYME posted strong Q2 earnings results on August 2. While EPS fell short of the consensus estimate by one cent, it was able to pull off a revenue beat.These results were boosted by a $7.5 million milestone payment from its partner Celgene (CELG) on July 16. The payment was triggered when CELG announced that it selected a lead oncology candidate and exercised its option for commercialization rights under their 2014 Azymetric agreement.After the news of the milestone payment broke, Deutsche Bank analyst Kostantinos Aprilakis told investors that the stock price represents a buying opportunity. This played into the analyst’s decision to initiate coverage with a Buy and set a $34 price target. He thinks shares could gain 36% in the next twelve months.In general, the Street takes a slightly more cautious stance on ZYME. It has a ‘Moderate Buy’ analyst consensus and a $29 average price target, suggesting 14% upside potential. Find analysts’ favorite stocks with the Top Analysts’ Stocks tool
- Zacks
Zymeworks Inc. (ZYME) Reports Q2 Loss, Tops Revenue Estimates
Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of -10.91% and 8.72%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
